ClinicalTrials.gg
CompletedNCT00413010Updated Feb 10, 2021Results posted

Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

A Phase 3 interventional study of pregabalin and placebo in Generalized Anxiety Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 68 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
48th of 234
356 · median 90
Started
2006
with 12 others
Phase 3
45 of 265
6 open now
Registered
38th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 48th largest by enrollment of the 234 interventional ones that give a count, is one of 13 that started in 2006, is one of 45 in phase 3, and was the 38th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 53 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD). Efficacy will be measured by the improvement in the total Hamilton Anxiety Rating Scale (HAM-A) scores from baseline observed following 8 weeks of double-blind treatment or at earlier termination during the double-blind treatment phase and analyzed using a mixed linear model for repeated measures.

Read the detailed description

Further enrollment in this study was stopped on January 28, 2008 based on the recommendation of an independent data monitoring committee. The recommendation to stop the study was not based on any safety findings.

03

Conditions studied

  • Generalized Anxiety Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male and female subjects with primary diagnosis of GAD, as confirmed by the MINI structured interview.
  • Historical failure to respond optimally to a GAD treatment

Exclusion criteria

Exclusion Criteria:

  • Current primary (Diagnostic and Statistical Manual of Mental Disorders 4th edition) diagnosis of major depressive disorder with or without seasonal pattern, dysthmic disorder, depressive disorder NOS (not otherwise specified), social phobia, panic disorder with or without agoraphobia, post traumatic stress disorder, dissociative disorder, borderline personality disorder, obsessive-compulsive disorder, antisocial personality disorder, as defined in the DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision).
  • Past and/or current DSM-IV diagnosis of schizophrenia, schizoaffective disorder, other psychotic disorders, bipolar disorders (I or II), factitious disorder or cognitive disorder (including delirium, dementia, and amnestic disorder).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
356 participants (actual)

Study arms

  • Placebo comparator
    Arm 2

    Drug: placebo

  • Experimental
    Arm 1

    Drug: pregabalin

Interventions

  • pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period

    Also known as: Lyrica

  • Drugplacebo

    placebo + concurrent GAD treatment from the open-label study period

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores

    Change from baseline: average across visit weeks using mixed model. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.

    Time frame: Baseline, 8 weeks

Secondary outcomes

  1. Change in HAM-A Total Score at Weekly Visits

    Change: score at each study week minus score at baseline. HAM-A, a clinician-rated interview, measures presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.

    Time frame: Baseline, Weeks 1 through Week 8

  2. Number of Responders Using Hamilton Anxiety Rating Scale (HAM-A)

    Responders = YES if subjects achieved a \>= 50% decrease in HAM-A total score from Baseline to respective study week. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; higher score indicates greater anxiety.

    Time frame: Weeks 1 through Week 8

  3. Subjects in Remission Using Hamilton Anxiety Rating Scale (HAM-A) Total Score

    Participant in remission defined as HAM-A total score of \<= 7. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges 0 - 56; higher score indicates greater anxiety.

    Time frame: Week 1 through Week 8

  4. Time to Onset of Sustained Hamilton Anxiety Rating Scale (HAM-A) Improvement

    Time to sustained improvement was defined as time to 50% or greater reduction in HAM-A total score from Baseline, which was sustained for the remainder of the study. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; a higher score indicates greater anxiety.

    Time frame: Week 8

  5. Number of Responders Using Clinical Global Impression of Improvement (CGI-I) Score

    Responders = YES using CGI-I if score indicated much improved or very much improved at the last study week. CGI-I is a clinician-rated instrument that measures change in subject's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 1 through Week 8

  6. Clinical Global Impression of Severity (CGI-S) Score

    CGI-S is a clinician-rated instrument measuring the severity of a subject's symptoms on a 7-point categorical scale. Scores range from 1 (not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill.

    Time frame: Week 8

  7. Change in Hamilton Depression Rating Scale (HAM-D) Total Score

    Change: score at each study week minus score at baseline. HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, \& weight loss). Total score ranges from 0 to 52; higher scores indicate more depression.

    Time frame: Weeks 1 through Week 8

07

Results

Posted Dec 2, 2009
Limitations and caveats
Further enrollment in this study was stopped based on the recommendation of an independent Data Monitoring Committee (DMC). An interim data analysis did not suggest the potential for robust efficacy. The study was not stopped for any safety findings.

Participant flow

The study was conducted in 55 centers in 8 countries (United States, Russian Federation, Czech Republic, Ukraine, Serbia, Hungary, Finland, and Estonia).

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started180176
Completed108113
Not completed7263
Withdrew: Adverse event84
Withdrew: Laboratory abnormality02
Withdrew: Lack of efficacy03
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject72
Withdrew: Due to termination of the study5452

Outcome measures

PrimaryChange in Hamilton Anxiety Rating Scale (HAM-A) Total Scores

Change from baseline: average across visit weeks using mixed model. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · score on scale
Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores
score on scalePregabalinPlacebo
Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores-7.6 ± 0.35-6.4 ± 0.36
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · Mean difference (final values): -1.2 · 95% CI -2.16 to -0.26Since an interim analysis was conducted and the sample size was larger than the targeted 173 subjects per group, a critical t-value adjustment was 1.977, yielding an adjusted 95% CI shown above.
SecondaryChange in HAM-A Total Score at Weekly Visits

Change: score at each study week minus score at baseline. HAM-A, a clinician-rated interview, measures presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety.

Time frame:
Baseline, Weeks 1 through Week 8
Reported as:
Least squares mean · score on scale
Change in HAM-A Total Score at Weekly Visits
score on scalePregabalinPlacebo
Week 1 (n=164;n=169)-4.4 ± 0.37-3.1 ± 0.37
Week 2 (n=166;n=163)-6.3 ± 0.43-5.2 ± 0.43
Week 3 (n=157;n=160)-7.0 ± 0.45-5.5 ± 0.45
Week 4 (n=153;n=150)-8.3 ± 0.46-7.0 ± 0.47
Week 5 (n=135;n=130)-8.4 ± 0.49-7.6 ± 0.49
Week 6 (n=122;n=125)-9.2 ± 0.49-8.0 ± 0.49
Week 8 (n=126;n=127)-9.3 ± 0.56-8.0 ± 0.56
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · Mean difference (final values): -1.33 · 95% CI -2.3 to -0.4Difference reflects pregabalin minus placebo.
  • Pregabalin vs Placebo · Mixed Models Analysis · Median difference (final values): -1.04 · 95% CI -2.2 to 0.1Difference reflects pregabalin minus placebo.
  • Pregabalin vs Placebo · Mixed Models Analysis · Mean difference (final values): -1.45 · 95% CI -2.7 to -0.2Difference reflects pregabalin minus placebo.
  • Pregabalin vs Placebo · Mixed Models Analysis · Mean difference (final values): -1.33 · 95% CI -2.6 to -0.1Difference reflects pregabalin minus placebo.
  • Pregabalin vs Placebo · Mixed Models Analysis · Mean difference (final values): -0.78 · 95% CI -2.1 to 0.5Difference reflects pregabalin minus placebo.
  • Pregabalin vs Placebo · Mixed Models Analysis · Mean difference (final values): -1.22 · 95% CI -2.5 to 0.1Difference reflects pregabalin minus placebo.
  • Pregabalin vs Placebo · Mixed Models Analysis · Mean difference (final values): -1.35 · 95% CI -2.9 to 0.2Difference reflects pregabalin minus placebo.
SecondaryNumber of Responders Using Hamilton Anxiety Rating Scale (HAM-A)

Responders = YES if subjects achieved a \>= 50% decrease in HAM-A total score from Baseline to respective study week. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; higher score indicates greater anxiety.

Time frame:
Weeks 1 through Week 8
Reported as:
Number · participants
Number of Responders Using Hamilton Anxiety Rating Scale (HAM-A)
participantsPregabalinPlacebo
Week 1 Responder: Yes218
Week 1 Responder: No143161
Week 2 Responder: Yes3926
Week 2 Responder: No127137
Week 3 Responder: Yes5123
Week 3 Responder: No106137
Week 4 Responder: Yes6446
Week 4 Responder: No89104
Week 5 Responder: Yes5846
Week 5 Responder: No7784
Week 6 Responder: Yes5748
Week 6 Responder: No6577
Week 8 Responder: Yes6347
Week 8 Responder: No6380
Week 8 (LOCF) Responder: Yes8462
Week 8 (LOCF) Responder: No93114
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 3.35 · 95% CI 1.37 to 8.24The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.61 · 95% CI 0.90 to 2.87The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 3.15 · 95% CI 1.76 to 5.66The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.80 · 95% CI 1.06 to 3.05The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.57 · 95% CI 0.90 to 2.73The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.52 · 95% CI 0.86 to 2.66The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.86 · 95% CI 1.08 to 3.22The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.77 · 95% CI 1.12 to 2.79The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
SecondarySubjects in Remission Using Hamilton Anxiety Rating Scale (HAM-A) Total Score

Participant in remission defined as HAM-A total score of \<= 7. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, \& restlessness. Total score ranges 0 - 56; higher score indicates greater anxiety.

Time frame:
Week 1 through Week 8
Reported as:
Number · participants
Subjects in Remission Using Hamilton Anxiety Rating Scale (HAM-A) Total Score
participantsPregabalinPlacebo
Week 1 Remission: Yes125
Week 1 Remission: No152164
Week 2 Remission: Yes2215
Week 2 Remission: No144148
Week 3 Remission: Yes3218
Week 3 Remission: No125142
Week 4 Remission: Yes4329
Week 4 Remission: No110121
Week 5 Remission: Yes3930
Week 5 Remission: No96100
Week 6 Remission: Yes3732
Week 6 Remission: No8593
Week 8 Remission: Yes4031
Week 8 Remission: No8696
Week 8 (LOCF) Remission: Yes5542
Week 8 (LOCF) Remission: No122134
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 2.88 · 95% CI 0.94 to 8.80The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.49 · 95% CI 0.72 to 3.06The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 2.08 · 95% CI 1.09 to 3.97The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.80 · 95% CI 0.99 to 3.28The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.53 · 95% CI 0.82 to 2.85The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.33 · 95% CI 0.71 to 2.48The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.55 · 95% CI 0.85 to 2.83The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.53 · 95% CI 0.92 to 2.53The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a remitter (yes) for pregabalin relative to the odds of being a remitter for placebo.
SecondaryTime to Onset of Sustained Hamilton Anxiety Rating Scale (HAM-A) Improvement

Time to sustained improvement was defined as time to 50% or greater reduction in HAM-A total score from Baseline, which was sustained for the remainder of the study. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; a higher score indicates greater anxiety.

Time frame:
Week 8
Reported as:
Median · days
Time to Onset of Sustained Hamilton Anxiety Rating Scale (HAM-A) Improvement
daysPregabalinPlacebo
Time to Onset of Sustained Hamilton Anxiety Rating Scale (HAM-A) Improvement57 (43.0 to 61.0)—
Statistical analysis
  • Pregabalin vs Placebo · Log Rank · p = 0.0137 (P-value corresponds to the 2-sided log-rank test.)2-sided log-rank test
SecondaryNumber of Responders Using Clinical Global Impression of Improvement (CGI-I) Score

Responders = YES using CGI-I if score indicated much improved or very much improved at the last study week. CGI-I is a clinician-rated instrument that measures change in subject's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 1 through Week 8
Reported as:
Number · participants
Number of Responders Using Clinical Global Impression of Improvement (CGI-I) Score
participantsPregabalinPlacebo
Week 1: Yes6249
Week 1: No101120
Week 2: Yes9474
Week 2: No7289
Week 3: Yes9376
Week 3: No6286
Week 4: Yes9788
Week 4: No5561
Week 5: Yes8981
Week 5: No4550
Week 6: Yes8376
Week 6: No3849
Week 8: Yes8082
Week 8: No4345
Week 8 (LOCF): Yes113110
Week 8 (LOCF): No6166
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.54 · 95% CI 0.96 to 2.47The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.58 · 95% CI 1.01 to 2.47The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.75 · 95% CI 1.09 to 2.82The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.26 · 95% CI 0.77 to 2.05The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.24 · 95% CI 0.72 to 2.11The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.45 · 95% CI 0.84 to 2.50The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.06 · 95% CI 0.61 to 1.84The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
  • Pregabalin vs Placebo · Regression, Logistic · Odds ratio (or): 1.12 · 95% CI 0.71 to 1.76The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. Odds of being a responder (yes) for pregabalin relative to the odds of being a responder for placebo.
SecondaryClinical Global Impression of Severity (CGI-S) Score

CGI-S is a clinician-rated instrument measuring the severity of a subject's symptoms on a 7-point categorical scale. Scores range from 1 (not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill.

Time frame:
Week 8
Reported as:
Number · participants
Clinical Global Impression of Severity (CGI-S) Score
participantsPregabalinPlacebo
Normal, not ill at all2818
Borderline, mentally ill4937
Mildly ill4963
Moderately ill4648
Markedly ill28
Severely ill21
Among the most extremely ill00
Not assessed01
Statistical analysis
  • Pregabalin vs Placebo · Cumulative Logit Model · Odds ratio (or): 1.56 · 95% CI 1.07 to 2.30The odds ratio represented the odds of demonstrating an improvement comparing pregabalin versus placebo. The odds of having an increasingly better response for pregabalin relative to the odds of having an increasingly better response for placebo.
SecondaryChange in Hamilton Depression Rating Scale (HAM-D) Total Score

Change: score at each study week minus score at baseline. HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, \& weight loss). Total score ranges from 0 to 52; higher scores indicate more depression.

Time frame:
Weeks 1 through Week 8
Reported as:
Least squares mean · score on scale
Change in Hamilton Depression Rating Scale (HAM-D) Total Score
score on scalePregabalinPlacebo
Week 1 n=165,168-2.1 ± 0.28-1.3 ± 0.28
Week 2 n=165,164-3.1 ± 0.30-2.4 ± 0.31
Week 3 n=156,160-3.5 ± 0.32-2.8 ± 0.32
Week 4 n=153, 149-4.7 ± 0.29-3.3 ± 0.29
Week 5 n=135, 130-4.3 ± 0.33-3.9 ± 0.34
Week 6 n=122, 125-4.7 ± 0.33-3.8 ± 0.33
Week 8 n= 126, 127-4.8 ± 0.40-3.8 ± 0.40
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): -0.8 · 95% CI -1.5 to 0.0Difference is pregabalin minus placebo.
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): -0.6 · 95% CI -1.5 to 0.2Difference is pregabalin minus placebo.
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): -0.7 · 95% CI -1.6 to 0.1Difference is pregabalin minus placebo.
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): -1.3 · 95% CI -2.1 to -0.6Difference is pregabalin minus placebo.
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): -0.4 · 95% CI -1.3 to 0.5Difference is pregabalin minus placebo.
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): -0.9 · 95% CI -1.8 to 0.0Difference is pregabalin minus placebo.
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): -1.0 · 95% CI -2.1 to 0.1Difference is pregabalin minus placebo.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin———
Placebo———
Most frequent serious events
Most frequent serious events
EventPregabalinPlacebo
DepressionPsychiatric disorders0/1801/176
Abdominal pain upperGastrointestinal disorders0/1801/176
Lower limb fractureInjury, poisoning and procedural complications0/1801/176
FallInjury, poisoning and procedural complications0/1801/176
Cardiac failure congestiveCardiac disorders1/1800/176
CellulitisInfections and infestations1/1800/176
Chronic Obstructive Pulmonary Disease (COPD)Respiratory, thoracic and mediastinal disorders1/1800/176
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders21/18010/176
HeadacheNervous system disorders17/1807/176
SomnolenceNervous system disorders15/1806/176
NauseaGastrointestinal disorders13/1808/176
Vision blurredEye disorders8/1802/176
DiarrheaGastrointestinal disorders7/1807/176
SedationNervous system disorders7/1807/176
FatigueGeneral disorders7/1805/176
NasopharyngitisInfections and infestations5/1806/176
Upper respiratory tract infectionInfections and infestations3/1806/176

Baseline characteristics

Age, Continuous
Age, Continuous(years)PregabalinPlaceboTotal
Mean43.7 ± 11.543.5 ± 12.543.6 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female129115244
Male5161112
08

Study locations

68 sites
  • Pfizer Investigational Site
    Arcadia, California 91007-3462, United States
  • Pfizer Investigational Site
    Burbank, California 91506, United States
  • Pfizer Investigational Site
    Redlands, California 92374, United States
  • Pfizer Investigational Site
    Sherman Oaks, California 91403, United States
  • Pfizer Investigational Site
    Norwich, Connecticut 06360, United States
  • Pfizer Investigational Site
    Destin, Florida 32541, United States
  • Pfizer Investigational Site
    Fort Walton Beach, Florida 32547, United States
  • Pfizer Investigational Site
    Miami, Florida 33143, United States
  • Pfizer Investigational Site
    South Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66212, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67207, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71101, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71104, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21208, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02114, United States
  • Pfizer Investigational Site
    Olive Branch, Mississippi 38654, United States
  • Pfizer Investigational Site
    Saint Charles, Missouri 63301, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68131, United States
  • Pfizer Investigational Site
    Clementon, New Jersey 08021, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Pfizer Investigational Site
    New York, New York 10128-1708, United States
  • Pfizer Investigational Site
    Beachwood, Ohio 44122, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45227, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44109-1998, United States
  • Pfizer Investigational Site
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Pfizer Investigational Site
    Media, Pennsylvania 19063, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19104-3309, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19136, United States
  • Pfizer Investigational Site
    Columbia, South Carolina 29201, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38117, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38133, United States
  • Pfizer Investigational Site
    Houston, Texas 77008, United States
  • Pfizer Investigational Site
    Houston, Texas 77074, United States
  • Pfizer Investigational Site
    Lake Jackson, Texas 77566, United States
  • Pfizer Investigational Site
    Waukesha, Wisconsin 53188-1660, United States
  • Pfizer Investigational Site
    Brno, 602 00, Czechia
  • Pfizer Investigational Site
    Litomerice, 412 01, Czechia
  • Pfizer Investigational Site
    Praha 2, 120 00, Czechia
  • Pfizer Investigational Site
    Praha 5, 158 00, Czechia
  • Pfizer Investigational Site
    Praha 6, 163 00, Czechia
  • Pfizer Investigational Site
    Praha 8 - Bohnice, 181 03, Czechia
  • Pfizer Investigational Site
    Viljandi, Viljandi Mk. 71024, Estonia
  • Pfizer Investigational Site
    Tallinn, 10614, Estonia
  • Pfizer Investigational Site
    Tartu, 50417, Estonia
  • Pfizer Investigational Site
    Helsinki, 00029 HUS, Finland
  • Pfizer Investigational Site
    Joensuu, 80100, Finland
  • Pfizer Investigational Site
    Kuopio, 70110, Finland
  • Pfizer Investigational Site
    Budapest, 1083, Hungary
  • Pfizer Investigational Site
    Budapest, 1137, Hungary
  • Pfizer Investigational Site
    Pecs, 7623, Hungary
  • Pfizer Investigational Site
    Moscow, 115522, Russian Federation
  • Pfizer Investigational Site
    Moscow, 119034, Russian Federation
  • Pfizer Investigational Site
    Moscow, 123367, Russian Federation
  • Pfizer Investigational Site
    Smolensk, 214018, Russian Federation
  • Pfizer Investigational Site
    Smolensk, 214019, Russian Federation
  • Pfizer Investigational Site
    St Petersburg, 190121, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 191180, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 192019, Russian Federation
  • Pfizer Investigational Site
    Belgrade, 11 000, Serbia
  • Pfizer Investigational Site
    Belgrade, 11000, Serbia
  • Pfizer Investigational Site
    Belgrade, Serbia
  • Pfizer Investigational Site
    Kragujevac, 34000, Serbia
  • Pfizer Investigational Site
    Dnipropetrovsk, 49005, Ukraine
  • Pfizer Investigational Site
    Dnipropetrovsk, 49115, Ukraine
  • Pfizer Investigational Site
    Donetsk, 83037, Ukraine
  • Pfizer Investigational Site
    Kyiv, 01030, Ukraine
  • Pfizer Investigational Site
    Lugansk, 91045, Ukraine
  • Pfizer Investigational Site
    Lviv, 79021, Ukraine
09

References and documents

Publications

  • Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012 May;27(3):142-50. doi: 10.1097/YIC.0b013e328350b133. PubMed 22302014 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Feb 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2006
First posted
Dec 19, 2006
Start
Dec 2006
Primary completionActual
Feb 2008
CompletionActual
Mar 2008
Results first posted
Dec 2, 2009
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00413010
Responsible party
Sponsor
First posted
Dec 19, 2006
Start date
Dec 2006
Primary completion
Feb 2008
Completion
Mar 2008
Results posted
Dec 2, 2009
Last update
Feb 10, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion